Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Open-label, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Patients With Hematological Malignancies

NCT00607152 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00607152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Open-label, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Patients With Hematological Malignancies
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2007
Completion date
January 31, 2009
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.